Acta Scientific Pharmaceutical Sciences (ASPS)(ISSN: 2581-5423)

Research Article Volume 4 Issue 7

Coronavirus Disease Pandemia 2019: Growth of Epidemic Dangers

VO Shapovalova1, SI Zbrozhek1, EV Suprun1, VV Shapovalov1-4* and VV Shapovalov5

1Kharkiv Medical Academy of Postgraduate Education, Kharkiv, Ukraine
2Ukrainian National Bar Association, Kyiv, Ukraine
3Advocates Company “Apotheosis”, Kharkiv, Ukraine
4Public Organization “Association of Medical and Pharmaceutical Law”, Kharkiv, Ukraine
5Healthcare Department of Kharkiv Regional State Administration, Kharkiv, Ukraine

*Corresponding Author: VV Shapovalov, Kharkiv Medical Academy of Postgraduate Education, Kharkiv, Ukraine.

Received: June 02, 2020; Published: July 01, 2020



The article is devoted to the problem of the emergence in 2019 of diseases caused by the new coronavirus (“coronavirus disease 2019”), which have already gone down in history as an emergency of international importance. The most common clinical manifestation of a new infection is pneumonia, and in a significant proportion of patients - respiratory distress syndrome. A virological, epidemiological and clinical study of severe acute respiratory syndrome, Middle East respiratory syndrome and the outbreak of acute respiratory diseasein 2019-2020 was compared in Wuhan (Hubei, People's Republic of China, China). Analysis of the scientific literature data on the coronavirus disease pandemic 2019 based on the systematization, synthesis and comparison of documentary data regarding: historical aspects of the study of coronaviruses; severe acute respiratory syndrome; Middle Eastern Respiratory Syndrome; SARS-CoV-2 virus disease COVID-19; comparative characteristics of SARS/MERS/COVID-19. When conducting the study, we used the current legislative, regulatory and instructive documents, Internet resources. They used regulatory, documentary, bibliographic, comparative and graphical methods of analysis. The article presents the results of a comparison of the virological, epidemiological and clinical studies of severe acute respiratory syndrome, Middle East respiratory syndrome and the outbreak of acute respiratory disease in 2019-2020 years in Wuhan (Hubei, People's Republic of China, China). Established that the etiological agent of COVID-19 is coronavirus, phylogenetically close to the causative agent of SARS (SARS-related human CoV virus) and related coronaviruses isolated from bats (SARS-related bat CoV viruses). The data obtained are the basis for the need to continue further research and reviews of the coronavirus pandemic in the direction of finding methods for effective treatment of patients with this pathology.

Keywords: Coronavirus; Epidemic Hazard; Pandemic; Severe Acute Respiratory Syndrome (SARS); Middle East Respiratory Syndrome (MERS); COVID-19 Diseases Caused by the SARS-CoV-2 Virus



  1. Chen Y and Guo D. “Molecular mechanisms of coronavirus RNA capping and methylation”. Virologica Sinica 31.3 (2016): 3-11.
  2. Woo PCY., et al. “Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus”. Journal of Virology 86 (2012): 3995-4008.
  3. Schalk AF and Hawn MC. “An apparently new respiratory disease of baby chicks”. Journal of the American Veterinary Medical Association 78 (1931): 19.
  4. “Virus Taxonomy. Classification and Nomenclature of Viruses. Ninth Report of the International Committee on Taxonomy of Viruses”. Eds. King A. M. Q., Adams M. J., Carstens E. B., Lefkowitz E. J. Elsevier Academic Press (2011): 1338.
  5. Baker DG. “Natural pathogens of laboratory mice, rats, and rabbits and their effects on research”. Clinical Microbiology Reviews 11 (1998): 231-266.
  6. Almeida JD., et al. “Virology: Coronaviruses”. Nature 220 (1968).
  7. Li F. “Structure, Function, and Evolution of Coronavirus Spike Proteins”. Annual Reviews of Virology 29 (2016): 237-261.
  8. Peiris JS., et al. “Coronavirus as a possible cause of severe acute respiratory syndrome”. Lancet 361.9366 (2003): 1319-1325.
  9. Hui DS and Zumla A. “Severe acute respiratory syndrome. Historical, epidemiologic, and clinical features”. Infectious Disease Clinics of North America 33.4 (2019): 869-889.
  10. Donnelly CA., et al. “Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong”. Lancet 361.9371 (2003): 1761-1766.
  11. Virology Guide. “Viruses and viral infections of humans and animals”. Ed. Lvov D.K. M.: MIA (2013): 1200.
  12. Zaki AM., et al. “Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia”. The New England Journal of Medicine 367.19 (2012): 1814-1820.
  13. Al-Abdallat MM., et al. “Hospital associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description”. Clinical Infection Disease 59 (2014): 1225-1233.
  14. World Health Organization. MERS situation update (2020).
  15. Mackay IM., et al. “MERS coronavirus: diagnostics, epidemiology and transmission”. Virology Journal 12 (2015): 222.
  16. Yin Y and Wunderink RG. “MERS, SARS and other coronaviruses as causes of pneumonia”. Respirology 23.2 (2018): 130-137.
  17. Cui J., et al. “Origin and evolution of pathogenic coronaviruses”. Nature Review on Microbiology 17 (2019): 181-192. 
  18. World Health Organization. Novel Coronavirus (2019-nCoV). Situation Report-10 (2020).
  19. JF Jhan., et al. “A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster”. Lancet 395 (2020): 514-523.
  20. GK Goh., et al. “Rigidity of the Outer Shell Predicted by a Protein Intrinsic Disorder Model Sheds Light on the COVID-19 (Wuhan-SARS-CoV-2) Infectivity”. Biomolecules 10 (2020).
  21. D Benvenuto., et al. “The global spread of 2019-nCoV: a molecular evolutionary analysis”. Pathology Global Health 12 (2020): 1-4. 
  22. X Xu., et al. “Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission”. Life Science (2020). 
  23. GW Guan., et al. “Exploring the mechanism of liver enzyme abnormalities in patients with novel coronavirus-infected pneumonia”. Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology 28 (2020). 
  24. DV Gorenkov., et al. “Outbreak of a new infectious disease COVID-19: β-coronaviruses as a threat to global health”. Biopreparations. Prevention, Diagnosis, Treatment 20 (2020): 6-20.


Citation: VV hapovalov., et al. “Coronavirus Disease Pandemia 2019: Growth of Epidemic Dangers". Acta Scientific Pharmaceutical Sciences 4.7 (2020): 61-68.


Acceptance rate32%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US